Dec 29 (Reuters) – Ultragenyx Pharmaceutical said on Monday that its experimental drug for a type of genetic bone disease did not meet the main goal in late-stage studies.
The company was testing the treatment called setrusumab in patients with osteogenesis imperfecta, a group of genetic disorders impacting bone metabolism.
The condition can result in increased bone brittleness, which contributes to a high rate of fractures.
The company said the drug failed to meet the main goal of significantly reducing annualized clinical fracture rate, compared to placebo.
Both studies, however, achieved the secondary goals of improvements in bone mineral density, the company said.
(Reporting by Sneha S K; Editing by Shailesh Kuber)
